Module 2 Legislation Grid

Posted on February 24, 2022 by Cheapest Assignment

Order Now
NUR325 Maternal Health and Paediatric

Part 1: Legislation Grid

Introduction

Biosimilars are a type of biological therapy thought to work similarly to an original biologic treatment. The similarity allows the people using actual biologic agents to easily switch to cheaper biosimilar products with no complications. Biosimilar is a term that was derived from a similar biological, medical product (Tieu et al., 2018).

Target priority population

Health-related Bill Name Advancing Education on Biosimilars Act of 2021
Bill Number S. 164
Description This Bill is an act to educate the public together with healthcare providers on biosimilar biological products and for other purposes.
Federal or State? Federal
Legislative Intent This Bill intends to explain the process of reporting adverse events for biological products that include integrable biosimilar biological products.

The legislation also intends to explain the relationship between biosimilar biological products and interchangeable biosimilar biological products (GovTrack.us., 2021).

Proponents/ Opponents Proponents: Health care providers, patients, and the caregivers.
Opponents: No opponents 
Target Population  The whole population of the United States both patients and healthcare professionals.
Status of the bill (Is it in hearings or committees?) The bill passed in the Senate on March 3, 2021, and is now heading to Congress next for consideration.
General Notes/Comments After the bill is passed by both the House and Senate, the president shall sign it to become law. The bill is sponsored by Maggie Hassan, a democrat and senator for New Hampshire (GovTrack.us., 2021).

Self-Management Priorities 

Part 2: Legislation Testimony/Advocacy Statement

Advocating for the bill I selected, I support its enaction into laws because of biosimilars’ benefits. The law shall offer opportunities to the general public that help reduce their health care costs as they uphold their standards of treatment. Furthermore, biosimilars reduce the savings in the health care system as a whole in comparison to a biologic (Milstead, 2019). However, the valuation of the savings of an individual majorly depends on the type of insurance coverage.

Conclusion

In conclusion, this bill may lack opponents to oppose it because most of the population lacks knowledge on what it entails. Educating the general public about being enacted under the law shall boost the necessary experience for the people to embrace this kind of therapy.

Preparation Stage of Successful Change

References

GovTrack.us. (2021). S. 164 — 117th Congress: Advancing Education on Biosimilars Act of 2021. Retrieved from https://www.govtrack.us/congress/bills/117/s164

Milstead, J. A. (Ed.). (2019). Health policy and politics: A nurse’s guide. Jones & Bartlett Learning.

Tieu, C., Lucas, E. J., DePaola, M., Rosman, L., & Alexander, G. C. (2018). Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review. PloS one, 13(4), e0195012.

 

Order Now